We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Karo Bio Announces that Merck & Co. Plans to Proceed With Phase II Clinical Evaluation of Candidate Compound

News   Nov 27, 2009

 
Karo Bio Announces that Merck & Co. Plans to Proceed With Phase II Clinical Evaluation of Candidate Compound
 
 
Advertisement
 

RELATED ARTICLES

Washington University COVID-19 Virus Effective in Mice

News

An experimental vaccine is effective at preventing pneumonia in mice infected with the COVID-19 virus, according to a study from Washington University School of Medicine in St. Louis

READ MORE

New Treatment Regimens Show Early Efficacy Against Drug-Resistant TB

News

New treatment regimens for multidrug-resistant tuberculosis have shown early effectiveness in 85% of patients in a cohort that included many with serious comorbidities.

READ MORE

Study Indicates a Lack of Diversity in COVID-19 Clinical Trials

News

Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials, according to a new study.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE